Abbott Laboratories reported a strong financial performance with significant growth in several segments, including medical devices and nutrition, while facing challenges from tariffs and a decline in diagnostics sales, particularly in China. The company's strategic investments and product innovations provide a solid foundation for future growth, although the impact of tariffs remains a concern.

Company Guidance -

Q2 2025

During Abbott Laboratories' First Quarter 2025 Earnings Conference Call, the company provided guidance that emphasized its resilient performance and strategic initiatives amid a dynamic economic environment. Abbott Laboratories reported a 7% increase in first-quarter sales, or more than 8% excluding COVID testing sales, and an 11% rise in adjusted earnings per share to $1.09, which was at the high end of their guidance range. The company achieved high single-digit sales growth and double-digit EPS growth, with gross margin expanding by 140 basis points and operating margin by 130 basis points compared to the prior year. Despite challenges such as new tariffs, Abbott Laboratories reaffirmed its full-year guidance, projecting adjusted earnings per share for the second quarter to be in the range of $1.23 to $1.27. The company highlighted its diverse business model's strength, with significant growth in medical devices (12.5%), diabetes care sales ($1.7 billion), and structural heart (15%). Abbott Laboratories is also making strategic investments, including half a billion dollars to expand its US transfusion diagnostic business, and is on track to launch more than 25 key new products over the next three years.

Strong Overall Financial Performance

Achieved target growth objective with high single-digit sales growth and double-digit earnings per share growth. First quarter sales grew 7% or more than 8% excluding COVID testing sales. Adjusted earnings per share of $1.09 grew 11% versus the prior year.

Nutrition Segment Growth

Sales increased 7% in the quarter, driven by high single-digit growth in adult nutrition and double-digit growth in US pediatric nutrition.

Medical Devices Surge

Sales grew 12.5%, with strong performance in diabetes care, structural heart, and electrophysiology segments. Continuous glucose monitors grew more than 20%, including 30% growth in the US.

Strategic Manufacturing and R&D Investments

On track to go live with two new manufacturing and R&D investments in Illinois and Texas by the end of the year, totaling half a billion dollars, to expand US transfusion diagnostic business.

Positive Developments in Electrophysiology and Structural Heart

Electrophysiology sales grew 10% with early Volt PFA system launch in Europe. Structural heart segment grew 15% with strong performance in surgical valves and transcatheter repair products.

Abbott Laboratories (ABT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 17, 2025	2025 (Q2)	1.25 / -	1.14	―	―	―
Apr 16, 2025	2025 (Q1)	1.07 / 1.09	0.98	11.22% (+0.11)
Jan 22, 2025	2024 (Q4)	1.34 / 1.34	1.19	12.61% (+0.15)
Oct 16, 2024	2024 (Q3)	1.20 / 1.21	1.14	6.14% (+0.07)
Jul 18, 2024	2024 (Q2)	1.10 / 1.14	1.08	5.56% (+0.06)
Apr 17, 2024	2024 (Q1)	0.95 / 0.98	1.03	-4.85% (-0.05)
Jan 24, 2024	2023 (Q4)	1.19 / 1.19	1.03	15.53% (+0.16)
Oct 18, 2023	2023 (Q3)	1.10 / 1.14	1.15	-0.87% (-0.01)
Jul 20, 2023	2023 (Q2)	1.05 / 1.08	1.43	-24.48% (-0.35)
Apr 19, 2023	2023 (Q1)	0.99 / 1.03	1.73	-40.46% (-0.70)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ABT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Apr 16, 2025	$126.22	$129.70	+2.76%
Jan 22, 2025	$116.25	$117.24	+0.85%
Oct 16, 2024	$114.91	$116.66	+1.52%
Jul 18, 2024	$103.17	$98.62	-4.41%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.